Related Experiment Video

Updated: Jun 2, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

The type 1 insulin-like growth factor receptor and resistance to DACH1

Tiziana DeAngelis1, Kongming Wu, Richard Pestell

  • 1Department of Cancer Biology, Jefferson Medical Center, Thomas Jefferson University, Philadelphia, PA, USA.

Cell Cycle (Georgetown, Tex.)
|May 12, 2011
PubMed

Insights

The dachshund homolog 1 (DACH1) gene acts as a tumor suppressor by downregulating EGFR and cyclin D1. However, DACH1 loses its tumor suppressor function in cancer cells reliant on the insulin-like growth factor 1 receptor (IGF-IR) pathway for growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The dachshund homolog 1 (DACH1) gene functions as a tumor suppressor in human breast and prostate cancers.
  • DACH1 is known to downregulate the epidermal growth factor receptor (EGFR) and cyclin D1.
  • The type 1 insulin-like growth factor receptor (IGF-IR) signaling pathway is implicated in resistance to EGFR-targeted cancer therapies.

Purpose of the Study:

  • To investigate whether DACH1 retains its tumor suppressor activity in cancer cells that depend on IGF-IR signaling for growth.
  • To determine the impact of IGF-IR dependency on DACH1's tumor suppressor function.

Main Methods:

  • Utilized cancer cell lines dependent on IGF-1 for growth.
  • Assessed the tumor suppressor activity of DACH1 in these cell lines.
  • Evaluated cellular response to EGF stimulation.

Main Results:

  • DACH1 exhibited no tumor suppressor activity in cancer cells reliant on IGF-1 for growth.
  • These cells were unresponsive to EGF, indicating a shift in growth signaling.
  • The findings suggest that IGF-IR signaling abrogates DACH1's tumor suppressor function.

Conclusions:

  • DACH1's tumor suppressor activity is lost in cancer cells dependent on IGF-IR signaling.
  • This loss of function may contribute to treatment resistance in cancers utilizing the IGF-IR pathway.
  • Targeting the IGF-IR pathway could be a strategy to restore DACH1's tumor suppressor function.

More Related Videos

Label-Free Imaging of Lipid Storage Dynamics in Caenorhabditis elegans using Stimulated Raman Scattering Microscopy10:59

Label-Free Imaging of Lipid Storage Dynamics in Caenorhabditis elegans using Stimulated Raman Scattering Microscopy

Published on: May 28, 2021

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...